ZNF536

Summary

ZNF536 (zinc finger protein 536, HGNC:29025) is a protein-coding gene on chromosome 19q12, encoding Zinc finger protein 536 (O15090). Transcriptional repressor that negatively regulates neuron differentiation by repressing retinoic acid-induced gene transcription.

The protein encoded by this gene is a highly conserved zinc finger protein. The encoded protein is most abundant in brain, where it negatively regulates neuronal differentiation.

Source: NCBI Gene 9745 — RefSeq curated summary.

At a glance

• GWAS associations: 31
• Clinical variants (ClinVar): 189 total
• MANE Select transcript: NM_014717

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29025
Approved symbol	ZNF536
Name	zinc finger protein 536
Location	19q12
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0390
Ensembl gene	ENSG00000198597
Ensembl biotype	protein_coding
OMIM	618037
Entrez	9745

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 12 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000355537, ENST00000585628, ENST00000590564, ENST00000591488, ENST00000592773, ENST00000706142, ENST00000706143, ENST00000706144, ENST00000706145, ENST00000706146, ENST00000706147, ENST00000706148, ENST00000706149, ENST00000706150

RefSeq mRNA: 4 — MANE Select: NM_014717 NM_001352260, NM_001376110, NM_001376111, NM_014717

CCDS: CCDS32984, CCDS92576, CCDS92577

Canonical transcript exons

ENST00000355537 — 5 exons

Exon	Start	End
ENSE00000694585	30534847	30534999
ENSE00001124181	30547943	30549514
ENSE00001351887	30557157	30558059
ENSE00001420211	30372384	30372556
ENSE00003994857	30443561	30445732

Expression profiles

Bgee: expression breadth ubiquitous, 184 present calls, max score 97.98.

FANTOM5 (CAGE): breadth broad, TPM avg 3.6753 / max 379.9191, expressed in 393 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
175025	1.7095	270
175030	0.6825	72
175022	0.6210	292
175026	0.2449	97
175024	0.2186	81
208769	0.0649	36
175028	0.0534	36
175029	0.0318	26
175027	0.0259	9
175023	0.0227	11

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	97.98	gold quality
pigmented layer of retina	UBERON:0001782	95.01	gold quality
corpus callosum	UBERON:0002336	93.69	gold quality
inferior vagus X ganglion	UBERON:0005363	93.67	gold quality
cerebellar vermis	UBERON:0004720	91.75	gold quality
sural nerve	UBERON:0015488	91.11	gold quality
pons	UBERON:0000988	91.09	gold quality
medulla oblongata	UBERON:0001896	90.28	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	89.99	gold quality
Brodmann (1909) area 46	UBERON:0006483	89.92	gold quality
spinal cord	UBERON:0002240	89.81	gold quality
superior vestibular nucleus	UBERON:0007227	89.65	gold quality
endothelial cell	CL:0000115	89.33	gold quality
trigeminal ganglion	UBERON:0001675	87.31	gold quality
dorsal root ganglion	UBERON:0000044	86.55	gold quality
substantia nigra pars reticulata	UBERON:0001966	86.46	gold quality
lateral globus pallidus	UBERON:0002476	86.39	gold quality
subthalamic nucleus	UBERON:0001906	86.29	gold quality
ventral tegmental area	UBERON:0002691	85.88	gold quality
midbrain	UBERON:0001891	85.84	gold quality
substantia nigra	UBERON:0002038	85.53	gold quality
cerebellum	UBERON:0002037	85.47	gold quality
globus pallidus	UBERON:0001875	85.20	gold quality
cerebellar cortex	UBERON:0002129	84.75	gold quality
cerebellar hemisphere	UBERON:0002245	84.57	gold quality
occipital lobe	UBERON:0002021	84.38	gold quality
substantia nigra pars compacta	UBERON:0001965	84.21	gold quality
medial globus pallidus	UBERON:0002477	84.11	gold quality
right hemisphere of cerebellum	UBERON:0014890	84.02	gold quality
Ammon’s horn	UBERON:0001954	83.66	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-93593	yes	301.20
E-HCAD-35	yes	89.19
E-ANND-3	yes	4.23

Regulation

Is transcription factor: yes

JASPAR motifs

Motif	Name	Family
MA2575.1	ZNF536	Factors with multiple dispersed zinc fingers

JASPAR matrix evidence (PMIDs): PMID:39605368

miRNA regulators (miRDB)

51 targeting ZNF536, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-4420	99.82	70.08	1624
HSA-MIR-181B-2-3P	99.81	70.06	1646
HSA-MIR-181B-3P	99.81	70.06	1646
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-1976	99.74	65.48	1127
HSA-MIR-7844-5P	99.55	68.56	1428
HSA-MIR-7159-5P	99.53	72.12	2472
HSA-MIR-8064	99.45	66.92	875
HSA-MIR-942-5P	99.41	68.40	1977
HSA-MIR-16-2-3P	99.29	70.60	1954
HSA-MIR-195-3P	99.29	70.61	1954
HSA-MIR-892C-5P	99.16	70.56	2116
HSA-MIR-4705	99.10	69.10	1091
HSA-MIR-4272	98.76	68.74	1810

Literature-anchored findings (GeneRIF, showing 2)

• ZFP536 promotes the late phase of oligodendrocyte differentiation. (PMID:17065439)
• Characterization of zinc finger protein 536, a neuroendocrine regulator, using pan-cancer analysis. (PMID:38720348)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	znf536	ENSDARG00000103648
mus_musculus	Zfp536	ENSMUSG00000043456
rattus_norvegicus	Zfp536	ENSRNOG00000014163

Paralogs (14): HIVEP2 (ENSG00000010818), HIVEP1 (ENSG00000095951), SALL4 (ENSG00000101115), ZNF516 (ENSG00000101493), SALL1 (ENSG00000103449), BCL11A (ENSG00000119866), ZNF831 (ENSG00000124203), RREB1 (ENSG00000124782), HIVEP3 (ENSG00000127124), BCL11B (ENSG00000127152), ZNF219 (ENSG00000165804), SALL2 (ENSG00000165821), ZNF217 (ENSG00000171940), SALL3 (ENSG00000256463)

Protein

Protein identifiers

Zinc finger protein 536 — O15090 (reviewed: O15090)

All UniProt accessions (7): O15090, A0A994J5C6, A0A994J5Q4, A0A994J7Z0, K7EJP8, K7EKT4, K7EQN6

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional repressor that negatively regulates neuron differentiation by repressing retinoic acid-induced gene transcription. Binds and interrupts RARA from binding to retinoic acid response elements (RARE) composed of tandem 5’-AGGTCA-3’ sites known as DR1-DR5. Recognizes and binds 2 copies of the core DNA sequence 5’-CCCCCA-3'.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (4): NP_001339189, NP_001363039, NP_001363040, NP_055532* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR051967	Krueppel_C2H2-ZF	Family

Pfam: PF00096, PF13909, PF16606

UniProt features (30 total): compositionally biased region 10, zinc finger region 9, region of interest 8, modified residue 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O15090-F1	47.76	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 826, 827

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 85 (showing top): GCM_PTPRD, BROWNE_HCMV_INFECTION_24HR_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, SABATES_COLORECTAL_ADENOMA_DN, IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR, GCM_PTK2, KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, LIU_PROSTATE_CANCER_DN, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3, MEISSNER_NPC_HCP_WITH_H3K4ME2_AND_H3K27ME3, ATGAAGG_MIR205, MIKKELSEN_IPS_WITH_HCP_H3K27ME3, MIKKELSEN_NPC_HCP_WITH_H3K27ME3, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II

GO Biological Process (4): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of DNA-templated transcription (GO:0006355), negative regulation of neuron differentiation (GO:0045665), negative regulation of retinoic acid receptor signaling pathway (GO:0048387)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), zinc ion binding (GO:0008270), retinoic acid-responsive element binding (GO:0044323), DNA binding (GO:0003677), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
neuron differentiation	1
negative regulation of cell differentiation	1
regulation of neuron differentiation	1
retinoic acid receptor signaling pathway	1
regulation of retinoic acid receptor signaling pathway	1
negative regulation of intracellular signal transduction	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
negative regulation of transcription by RNA polymerase II	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription repressor activity	1
transition metal ion binding	1
RNA polymerase II cis-regulatory region sequence-specific DNA binding	1
nucleic acid binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1248 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF536	ZNF687	Q8N1G0	526
ZNF536	FAM181B	A6NEQ2	490
ZNF536	ZNF592	Q92610	490
ZNF536	NAV3	Q8IVL0	448
ZNF536	CSMD1	Q96PZ7	419
ZNF536	CC2D1A	Q6P1N0	418
ZNF536	BBX	Q8WY36	412
ZNF536	DISP3	Q9P2K9	400
ZNF536	CSMD3	Q7Z407	398
ZNF536	SERGEF	Q9UGK8	397
ZNF536	XIRP2	A4UGR9	394
ZNF536	ZNF804A	Q7Z570	389
ZNF536	FBXO2	Q9UK22	385
ZNF536	TSHZ3	Q63HK5	380
ZNF536	TBC1D15	Q8TC07	377

IntAct

40 interactions, top by confidence:

A	B	Type	Score
EN1	NFIB	psi-mi:“MI:2364”(proximity)	0.470
ZNF536	H1-1	psi-mi:“MI:0915”(physical association)	0.400
ZNF536	H1-5	psi-mi:“MI:0915”(physical association)	0.400
FOXC2	ZNF536	psi-mi:“MI:0914”(association)	0.350
FOXJ2	TCERG1	psi-mi:“MI:0914”(association)	0.350
TEAD2	DDX39A	psi-mi:“MI:0914”(association)	0.350
SOX2	CBX4	psi-mi:“MI:0914”(association)	0.350
DYRK1A	TEX13D	psi-mi:“MI:0914”(association)	0.350
CALM2	MYO1C	psi-mi:“MI:0914”(association)	0.350
CALM3	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
DBNL	ZNF536	psi-mi:“MI:0914”(association)	0.350
S100B	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350
SLC1A3	DDX11L8	psi-mi:“MI:0914”(association)	0.350
SLC22A11	CNOT1	psi-mi:“MI:0914”(association)	0.350
SLC39A12	ESYT2	psi-mi:“MI:0914”(association)	0.350
TBXT	BCL9	psi-mi:“MI:2364”(proximity)	0.270
FOXI1	BCL9	psi-mi:“MI:2364”(proximity)	0.270
FOXL1	PGRMC1	psi-mi:“MI:2364”(proximity)	0.270
GATA2	BCL9	psi-mi:“MI:2364”(proximity)	0.270
GATA3	BCL9	psi-mi:“MI:2364”(proximity)	0.270
GCM1	BCL9	psi-mi:“MI:2364”(proximity)	0.270
HNF1B	BCL9	psi-mi:“MI:2364”(proximity)	0.270
KLF12		psi-mi:“MI:2364”(proximity)	0.270
KLF3	MCRIP1	psi-mi:“MI:2364”(proximity)	0.270
LHX2	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
LHX6	BCL9	psi-mi:“MI:2364”(proximity)	0.270
MYB	KMT2D	psi-mi:“MI:2364”(proximity)	0.270
MYC	SETD1A	psi-mi:“MI:2364”(proximity)	0.270
NFIX	TAF4	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (79): ZNF536 (Affinity Capture-MS), ZNF536 (Affinity Capture-MS), ZNF536 (Affinity Capture-MS), ZNF536 (Proximity Label-MS), ZNF536 (Proximity Label-MS), ZNF536 (Synthetic Lethality), HIST1H1A (Proximity Label-MS), HIST1H1B (Proximity Label-MS), ZNF536 (Proximity Label-MS), ZNF536 (Proximity Label-MS), ZNF536 (Affinity Capture-MS), ZNF536 (Affinity Capture-MS), ZNF536 (Proximity Label-MS), ZNF536 (Affinity Capture-RNA), ZNF536 (Proximity Label-MS)

ESM2 similar proteins: A0JPB4, A0PJY2, B0K011, O08876, O15090, O57415, O62651, O70237, O75626, O95863, P19544, P22561, P41183, P49952, P55878, P86413, Q02085, Q08DS3, Q0IHB8, Q0P4W9, Q0VDQ9, Q25C93, Q28G88, Q2TAR3, Q2VWH6, Q32NK7, Q3MHQ4, Q3T135, Q3UH06, Q567J8, Q5T0B9, Q5VTD9, Q5XJQ7, Q60636, Q62255, Q66JF8, Q6AY34, Q6DBW0, Q6NRM0, Q804Q5

Diamond homologs: A1L2U9, A2A884, A2ANX9, B0X0K1, B0X9H6, B0XS89, B1WAZ8, B1WBU4, E9PZZ1, E9Q6W4, G5EBU4, O15090, O60315, O62836, O73694, O75362, O77459, P08048, P10925, P15822, P17010, P17012, P20662, P26635, P28166, P28575, P28698, P31509, P31629, P36197, P52739, P53243, P60319, P78871, P80944, Q00453, Q00900, Q01800, Q02026, Q02027

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 58 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of miRNA transcription	7	37.0×	1e-07
anatomical structure morphogenesis	7	17.7×	1e-05
transcription by RNA polymerase II	9	11.5×	8e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

189 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	161
Likely benign	15
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

1965 predictions. Top by Δscore:

Variant	Effect	Δscore
19:30443555:TTTCA:T	acceptor_loss	0.9900
19:30443556:TTCAG:T	acceptor_loss	0.9900
19:30443557:TCAGG:T	acceptor_loss	0.9900
19:30443558:CAG:C	acceptor_loss	0.9900
19:30443559:A:AG	acceptor_gain	0.9900
19:30443559:A:C	acceptor_loss	0.9900
19:30443559:AG:A	acceptor_gain	0.9900
19:30443559:AGG:A	acceptor_gain	0.9900
19:30443560:G:GG	acceptor_gain	0.9900
19:30443560:GG:G	acceptor_gain	0.9900
19:30443560:GGG:G	acceptor_gain	0.9900
19:30443560:GGGAT:G	acceptor_gain	0.9900
19:30445733:G:GC	donor_loss	0.9900
19:30445734:T:G	donor_loss	0.9900
19:30534845:A:AG	acceptor_gain	0.9900
19:30534846:G:GG	acceptor_gain	0.9900
19:30534846:GAC:G	acceptor_gain	0.9900
19:30534997:CAGGT:C	donor_loss	0.9900
19:30534998:AG:A	donor_loss	0.9900
19:30547927:T:G	acceptor_gain	0.9900
19:30549510:GTGTG:G	donor_gain	0.9900
19:30549512:GTG:G	donor_gain	0.9900
19:30549513:TGGTA:T	donor_loss	0.9900
19:30549514:GGTAA:G	donor_loss	0.9900
19:30549515:G:C	donor_loss	0.9900
19:30549515:G:GG	donor_gain	0.9900
19:30549516:T:A	donor_loss	0.9900
19:30534839:C:CA	acceptor_gain	0.9800
19:30540865:G:T	donor_gain	0.9800
19:30547929:T:G	acceptor_gain	0.9800

AlphaMissense

8607 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:30443950:T:G	Y130D	1.000
19:30443951:A:G	Y130C	1.000
19:30443956:T:A	C132S	1.000
19:30443956:T:C	C132R	1.000
19:30443956:T:G	C132G	1.000
19:30443957:G:A	C132Y	1.000
19:30443957:G:C	C132S	1.000
19:30443957:G:T	C132F	1.000
19:30443958:C:G	C132W	1.000
19:30443965:T:A	C135S	1.000
19:30443965:T:C	C135R	1.000
19:30443966:G:A	C135Y	1.000
19:30443966:G:C	C135S	1.000
19:30443966:G:T	C135F	1.000
19:30443967:C:G	C135W	1.000
19:30443971:A:G	K137E	1.000
19:30443973:G:C	K137N	1.000
19:30443973:G:T	K137N	1.000
19:30443977:T:A	F139I	1.000
19:30443977:T:C	F139L	1.000
19:30443977:T:G	F139V	1.000
19:30443978:T:C	F139S	1.000
19:30443978:T:G	F139C	1.000
19:30443979:C:A	F139L	1.000
19:30443979:C:G	F139L	1.000
19:30443983:T:A	F141I	1.000
19:30443983:T:C	F141L	1.000
19:30443983:T:G	F141V	1.000
19:30443984:T:C	F141S	1.000
19:30443984:T:G	F141C	1.000

dbSNP variants (sampled 300 via entrez): RS1000008250 (19:30360436 C>T), RS1000009871 (19:30599647 A>G), RS1000012866 (19:30513901 A>G), RS1000029316 (19:30388208 A>C), RS1000031214 (19:30283801 T>C), RS1000036404 (19:30401745 A>G), RS1000038288 (19:30345562 C>T), RS1000040267 (19:30367109 C>T), RS1000043298 (19:30660192 G>A), RS1000047886 (19:30243191 A>C,G), RS1000051553 (19:30460117 C>T), RS1000053261 (19:30520932 G>A), RS1000057016 (19:30624091 G>C,T), RS1000069158 (19:30594040 C>T), RS1000069241 (19:30672815 C>A,G)

Disease associations

OMIM: gene MIM:618037 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

31 associations (top):

Study	Trait	p-value
GCST000083_17	Select biomarker traits	8.000000e-07
GCST001712_61	Myopia (pathological)	3.000000e-12
GCST001762_72	Obesity-related traits	5.000000e-06
GCST001998_3	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)	3.000000e-06
GCST002491_8	Age-related hearing impairment	7.000000e-06
GCST002539_90	Schizophrenia	4.000000e-09
GCST002783_107	Body mass index	2.000000e-06
GCST002783_192	Body mass index	1.000000e-06
GCST002783_347	Body mass index	8.000000e-07
GCST003206_1	Myocardial infarction in hypertension (calcium channel blocker interaction)	4.000000e-07
GCST003564_5	Waist-to-hip ratio adjusted for body mass index	1.000000e-06
GCST003989_17	Chin dimples	3.000000e-15
GCST004070_18	Cerebrospinal P-tau181p levels	9.000000e-06
GCST004904_203	Body mass index	8.000000e-10
GCST004946_98	Schizophrenia	5.000000e-09
GCST005356_3	Severe malaria	9.000000e-07
GCST005357_13	Severe malaria (adjusted for sickle cell variant rs334)	4.000000e-06
GCST006041_39	Major depressive disorder	2.000000e-06
GCST006266_1	Remission after SSRI treatment in major depression	1.000000e-06
GCST006803_57	Schizophrenia	2.000000e-10
GCST007201_262	Schizophrenia	5.000000e-09
GCST007201_318	Schizophrenia	2.000000e-08
GCST007325_102	General risk tolerance (MTAG)	2.000000e-10
GCST007576_166	Chronotype	4.000000e-09
GCST007576_41	Chronotype	2.000000e-08
GCST008554_8	Atorvastatin-induced myopathy	1.000000e-06
GCST010988_21	Adult body size	1.000000e-13
GCST010989_291	Body size at age 10	9.000000e-10
GCST012049_1	High density lipoprotein cholesterol levels	4.000000e-07
GCST90012857_15	Falling risk	7.000000e-07

EFO canonical traits (12, from GWAS)

EFO ID	Trait name
EFO:0004458	C-reactive protein measurement
EFO:0004207	pathological myopia
EFO:0004340	body mass index
EFO:0007767	response to calcium channel blocker
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0004763	p-tau measurement
EFO:0005658	response to selective serotonin reuptake inhibitor
EFO:0008579	risk-taking behaviour
EFO:0008328	chronotype measurement
EFO:0009819	comparative body size at age 10, self-reported
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0007789	BMI-adjusted waist circumference

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs185430475	ZNF536		0.00	0

CTD chemical–gene interactions

10 total (human), top 10 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases methylation	2
ethyl-p-hydroxybenzoate	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
Sunitinib	decreases expression	1
Lipopolysaccharides	decreases expression, affects response to substance, increases expression, affects cotreatment	1
Tunicamycin	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E2PU	HAP1 ZNF536 (-) 2	Cancer cell line	Male
CVCL_XV33	HAP1 ZNF536 (-) 1	Cancer cell line	Male

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice